Literature DB >> 35441134

β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.

Chenyang Jiang1, Qingyong Wang2, Siwei Xie1, Zhicheng Chen3, Liping Fu4, Qiyu Peng1, Ying Liang5, Hongbo Guo6, Tengfei Guo1,7.   

Abstract

Extracellular β-amyloid plaques and intracellular neurofibrillary tau tangles are the primary hallmarks of Alzheimer's disease. β-Amyloid pathology can be directly quantified by positron emission tomography imaging or indirectly by measuring the decrease of cerebrospinal fluid β-amyloid42/β-amyloid40 ratio. Although these two β-amyloid biomarkers may be considered interchangeable, they sometimes show discordance, particularly in early stage of Alzheimer's disease. Individuals with cerebrospinal fluid β-amyloid positive only or β-amyloid positron emission tomography positive only may be at early amyloidosis stage compared to those who are cerebrospinal fluid β-amyloid negative and β-amyloid positron emission tomography negative orcerebrospinal fluid β-amyloid positive and β-amyloid positron emission tomography positive. Besides, β-amyloid pathology may play an initiating role in Alzheimer's disease onset, leading to subsequent tau increases. However, it is still unclear whether individuals with different β-amyloid pathways have distinct spatial patterns of cortical tau tangles in early amyloidosis stage. In this study, we analyzed 238 cognitively unimpaired and 77 mild cognitive impairment individuals with concurrent (interval of acquisition <1 year) 18F-flortaucipir tau positron emission tomography, β-amyloid (18F-florbetapir or 18F-florbetaben) positron emission tomography and cerebrospinal fluid β-amyloid42 and β-amyloid40 and cerebrospinal fluid p-Tau181 and divided them into four different cerebrospinal fluid/positron emission tomography groups based on the abnormal status of cerebrospinal fluid β-amyloid42/β-amyloid40 (cerebrospinal fluid±) and β-amyloid positron emission tomography (±). We determined the cortical regions with significant tau elevations of different cerebrospinal fluid/positron emission tomography groups and investigated the region-wise and voxel-wise associations of tau positron emission tomography images with cerebrospinal fluid β-amyloid42/β-amyloid40, β-amyloid positron emission tomography and cerebrospinal fluid p-Tau/β-amyloid40 in early (cerebrospinal fluid positive/positron emission tomography negative and cerebrospinal fluid negative/positron emission tomography positive) and late (cerebrospinal fluid positive/positron emission tomography positive) amyloidosis stages. By compared to the cerebrospinal fluid negative/positron emission tomography negative individuals (Ref) without evidence of tau increase measured by cerebrospinal fluid or positron emission tomography, cerebrospinal fluid positive/positron emission tomography negative individuals showed higher tau in entorhinal but not in BraakIII/IV and BraakV/VI, whereas cerebrospinal fluid negative/positron emission tomography positive individuals had significant tau elevations in BraakV/VI but not in entorhinal and BraakIII/IV. In contrast, cerebrospinal fluid positive/positron emission tomography positive individuals showed significant tau increases in all the cortical regions than the Ref group. The voxel-wise analyses provided further evidence that lower cerebrospinal fluid β-amyloid42/β-amyloid40 was associated with higher tau in entorhinal, whilst higher β-amyloid positron emission tomography was related to higher tau in BraakV/VI regions in early amyloidosis stage. Both lower cerebrospinal fluid β-amyloid42/β-amyloid40 and higher β-amyloid positron emission tomography were correlated with tau aggregation in all the Braak stages regions in late amyloidosis stage. These findings provide novel insights into the spatial patterns of cortical tau tangles in different amyloidosis stages of Alzheimer's disease, suggesting cerebrospinal fluid β-amyloid and β-amyloid positron emission tomography discordant groups may have distinct characteristics of cortical tau tangles in early amyloidosis stage.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

Entities:  

Keywords:  Alzheimer's disease; Tau; cerebrospinal fluid; positron emission tomography imaging; β-amyloid

Year:  2022        PMID: 35441134      PMCID: PMC9014538          DOI: 10.1093/braincomms/fcac084

Source DB:  PubMed          Journal:  Brain Commun        ISSN: 2632-1297


  64 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET.

Authors:  Josef Pannee; Erik Portelius; Lennart Minthon; Johan Gobom; Ulf Andreasson; Henrik Zetterberg; Oskar Hansson; Kaj Blennow
Journal:  J Neurochem       Date:  2016-09-30       Impact factor: 5.372

3.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

4.  Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.

Authors:  Marissa D Zwan; Juha O Rinne; Steen G Hasselbalch; Agneta Nordberg; Alberto Lleó; Sanna-Kaisa Herukka; Hilkka Soininen; Ian Law; Justyna M C Bahl; Stephen F Carter; Juan Fortea; Rafael Blesa; Charlotte E Teunissen; Femke H Bouwman; Bart N M van Berckel; Pieter J Visser
Journal:  Neurology       Date:  2015-10-14       Impact factor: 9.910

5.  Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.

Authors:  Pierre-François Meyer; Alexa Pichet Binette; Julie Gonneaud; John C S Breitner; Sylvia Villeneuve
Journal:  JAMA Neurol       Date:  2020-04-01       Impact factor: 18.302

6.  Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.

Authors:  Antoine Leuzy; Konstantinos Chiotis; Steen G Hasselbalch; Juha O Rinne; Alexandre de Mendonça; Markus Otto; Alberto Lleó; Miguel Castelo-Branco; Isabel Santana; Jarkko Johansson; Sarah Anderl-Straub; Christine A F von Arnim; Ambros Beer; Rafael Blesa; Juan Fortea; Sanna-Kaisa Herukka; Erik Portelius; Josef Pannee; Henrik Zetterberg; Kaj Blennow; Agneta Nordberg
Journal:  Brain       Date:  2016-07-07       Impact factor: 13.501

7.  Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.

Authors:  Piotr Lewczuk; Anja Matzen; Kaj Blennow; Lucilla Parnetti; Jose Luis Molinuevo; Paolo Eusebi; Johannes Kornhuber; John C Morris; Anne M Fagan
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 8.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

9.  Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Authors:  Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman
Journal:  EMBO Mol Med       Date:  2009-11       Impact factor: 12.137

10.  The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.

Authors:  Ellis Niemantsverdriet; Julie Ottoy; Charisse Somers; Ellen De Roeck; Hanne Struyfs; Femke Soetewey; Jeroen Verhaeghe; Tobi Van den Bossche; Sara Van Mossevelde; Johan Goeman; Peter Paul De Deyn; Peter Mariën; Jan Versijpt; Kristel Sleegers; Christine Van Broeckhoven; Leonie Wyffels; Adrien Albert; Sarah Ceyssens; Sigrid Stroobants; Steven Staelens; Maria Bjerke; Sebastiaan Engelborghs
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.